A low-dose β1-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation

Cardiology (Switzerland)

Volumn 127, Issue 2, 2014, Pages 105-113

  Kobayashi, Shigeki ^a   Murakami, Wakako ^a   Myoren, Takeki ^a   Tateishi, Hiroki ^a   Okuda, Shinichi ^a   Doi, Masahiro ^a   Nao, Tomoko ^a   Wada, Yasuaki ^a   Matsuzaki, Masunori ^a   Yano, Masafumi ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Blocker; Acute decompensated heart failure; Atrial fibrillation; Tachycardia

Indexed keywords

AMIODARONE; ATRIAL NATRIURETIC FACTOR ALPHA; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; EPLERENONE; GLYCERYL TRINITRATE; LANDIOLOL; LOOP DIURETIC AGENT; MILRINONE; NITROPRUSSIDE SODIUM; SPIRONOLACTONE; VASODILATOR AGENT; DIGITALIS;

ACUTE HEART FAILURE; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIASTOLIC HEART FAILURE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; LOW DRUG DOSE; MALE; NEW YORK HEART ASSOCIATION CLASS; PAROXYSMAL HEART ATRIUM FIBRILLATION; PRIORITY JOURNAL; SINUS RHYTHM; SYSTOLIC HEART FAILURE; TACHYCARDIA; ARTERIAL PRESSURE; CLINICAL STUDY; CONTROLLED STUDY; DRUG TOLERANCE; ELECTROCARDIOGRAM; HEART ATRIOVENTRICULAR NODE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION TIME; SINUS TACHYCARDIA;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; AGED; ATRIAL FIBRILLATION; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; MORPHOLINES; UREA;

EID: 84893311609     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000355312     Document Type: Article

References (34)

1. Fujita T, Ishikawa Y: Apoptosis in heart failure: the role of the β-adrenergic receptor-mediated signaling pathway and p53-mediated signaling pathway in the apoptosis of cardiomyocytes. Circ J 2011; 75: 1811-1818.
2. Maytin M, Colucci WS: Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005; 96: 26G-31G.
3. Selby DE, Palmer BM, LeWinter MM, Meyer M: Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction. J Am Coll Cardiol 2011; 58: 147-154.
4. Andersson B, Lomsky M, Waagstein F: The link between acute haemodynamic adrenergic beta-blockade and long-term effects in patients with heart failure: a study on diastolic function, heart rate and myocardial metabolism following intravenous metoprolol. Eur Heart J 1993; 14: 1375-1385.
5. Majure DT, Teerlink JR: Update on the management of acute decompensated heart failure. Curr Treat Options Cardiovasc Med 2011;13:570-585.
6. Thomas SS, Nohria A: Hemodynamic classifications of acute heart failure and their clinical application: an update. Circ J 2012; 76: 278-286.
7. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, ESC Committee for Practice Guidelines (CPG): ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology - developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
8. Hiramitsu S, Miyagishima K, Kimura H, Mori K, Shiino K, Yamada A, Kato S, Kato Y, Morimoto S, Hishida H, Ozaki Y: Management of severe heart failure. Circ J 2009; 73(suppl A):A36-A41.
9. Sun H, Chartier D, Leblanc N, Nattel S: Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. Cardiovasc Res 2001; 49: 751-761.
10. Mochizuki M, Yano M, Oda T, Tateishi H, Kobayashi S, Yamamoto T, Ikeda Y, Ohkusa T, Ikemoto N, Matsuzaki M: Scavenging free radicals by low-dose carvedilol prevents redox- dependent Ca 2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 2007; 49: 1722-1732.
11. Hasenfuss G, Reinecke H, Studer R, Pieske B, Meyer M, Drexler H, Just H: Calcium cycling proteins and force-frequency relationship in heart failure. Basic Res Cardiol 1996; 91(suppl 2):17-22.
12. Hull HB, Oser BM, Ryan JM, Schieve JF: Experiences with pulsus alternans: ventricular alternation and the stage of heart failure. Circulation 1956; 14: 1099-1103.
13. Kobayashi S, Susa T, Tanaka T, Murakami W, Fukuta S, Okuda S, Doi M, Wada Y, Nao T, Yamada J, Okamura T, Yano M, Matsuzaki M: A low-dose β -blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. Circ J 2012; 76: 1646-1653.
14. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, ESC Committee for Practice Guidelines: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
15. Yoshida Y, Hongo T, Sakamoto A, Ogawa R: Successful management of tachycardia atrial fibrillation in a septic patient with landiolol. Anesth Analg 2005; 100: 294-295.
16. Yoshida Y, Terajima K, Sato C, Akada S, Miyagi Y, Hongo T, Takeda S, Tanaka K, Sakamoto A: Clinical role and efficacy of landiolol in the intensive care unit. J Anesth 2008; 22: 64-69.
17. Ikeshita K, Nishikawa K, Toriyama S, Yamashita T, Tani Y, Yamada T, Asada A: Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts. J Anesth 2008; 22: 361-366.
18. Shibata S, Okamoto Y, Endo S, Ono K: Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts. J Pharmacol Sci 2012; 118: 255-265.
19. Intravenous digoxin in acute atrial fibrillation: results of a randomized, placebo-controlled multicentre trial in 239 patients - the Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J 1997; 18: 649-654.
20. Hofmann R, Steinwender C, Kammler J, Kypta A, Leisch F: Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. Int J Cardiol 2006; 110: 27-32.
21. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, Woosley RL: Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: a randomized, digoxin-controlled study. Eur Heart J 1995; 16: 521-528.
22. Ronco C, Cicoira M, McCullough PA: Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 2012; 60: 1031-1042.
23. Leroy G, Haiat R, Barthelemy M, Lionnet F: Torsade de pointes during loading with amiodarone. Eur Heart J 1987; 8: 541-543.
24. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ: Digoxin for converting recent- onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med 1987; 106: 503-506.
25. Sakaguchi M, Sasaki Y, Hirai H, Hosono M, Nakahira A, Seo H, Suehiro S: Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery. Int Heart J 2012; 53: 359-363.
26. Sakamoto A, Kitakaze M, Takamoto S, Namiki A, Kasanuki H, Hosoda S, JL-KNIGHT study group: Landiolol, an ultra-short-acting β1-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study). Circ J 2012; 76: 1097-1101.
27. Dobrev D, Voigt N, Wehrens XH: The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. Cardiovasc Res 2011; 89: 734-743.
28. Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings M, Rienstra M, Groenveld HF, Van den Berg MP, Van Gelder IC, for the RACEII investigators: Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study. Eur J Heart Fail 2013;15: 1311-1318 .
29. Suman-Horduna I, Roy D, Frasure-Smith N, Talajic M, Lesperance F, Blondeau L, Dorian P, Khairy P, AF-CHF Trial Investigators: Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. J Am Coll Cardiol 2013; 61: 455- 460.
30. Rawles JM: What is meant by a 'controlled' ventricular rate in atrial fibrillation? Br Heart J 1990; 63: 157-161.
31. Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M, J-Land Investigators: Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-shortacting β 1 -selective blocker landiolol with digoxin (J-Land Study). Circ J 2013; 77: 908-916.
32. O'Keefe JH Jr, Magalski A, Stevens TL, Bresnahan DR Jr, Alaswad K, Krueger SK, Bateman TM: Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure. J Nucl Cardiol 2000; 7: 3-7.
33. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651- 1658.
34. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M, IMPACT-HF Investigators and Coordinators: Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure - results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. Am Coll Cardiol 2004; 43: 1534-1541.